Overall rank by patents
#39,997
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, active 2024–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B32B (LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM).
The verdict
EPL holds 6 US patents across 2 technology areas, rank #39,997 of 50,000 tracked assignees.
EPL Limited has been granted 6 US utility patents between 2024 and 2025, placing EPL Limited at rank #39,997 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.3 claims per patent with primary concentration in B32B (LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM). As a Foreign Corporation, EPL Limited is one of the more focused assignees in the PatentsView dataset. By volume, EPL sits between Epics Therapeutics (6 patents, rank #39,993) and Equus Motors, Llc. (6 patents, rank #40,001) - the closest US assignees by grant volume. The composite Innovation Score of 28.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2024 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. EPL Limited's 5.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark EPL Limited against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
EPICS THERAPEUTICS
6 patents
EPIGEN Biosciences, Inc.
6 patents
EPIR, INC.
6 patents
EPISYS SCIENCE, INC.
6 patents
EPtronics, Inc.
6 patents
EQUI-NOM LTD
6 patents
EQUIPMOUNT LLC
6 patents
EQUUS Motors, LLC.
6 patents
EPL LIMITED
6 patents
What this shows EPL holds 6 patents at rank #39,997, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #39,997 in granted patent volume.
Other assignees with the most granted patents in EPL's primary technology class.
EPL's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
28 Top 73% higher than 27% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2024 | 2 | 33.3% |
| 2025 | 4 | 66.7% |
Top 2 of 2 technology areas
Overall rank by patents
#39,997
Across all tracked assignees
28.3 out of 100
How to use this portfolio
EPL's 6 grants land it in the top 73% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.